Prevalence and characteristics of Kawasaki disease before and during the COVID-19 pandemic

Springer Science and Business Media LLC - Tập 17 - Trang 215-217 - 2021
Rintaro Ono1, Daisuke Hasegawa
1Department of Pediatrics, St. Luke’s International Hospital, Tokyo, Japan

Tài liệu tham khảo

Rowley AH, Wylie KM, Kim KY, Pink AJ, Yang A, Reindel R, et al. The transcriptional profile of coronary arteritis in Kawasaki disease. BMC Genomics. 2015;16:1076. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int. 2005;47:232–4. Kobayashi T, Saji T, Otani T, Takeuchi K, Nakamura T, Arakawa H, et al. Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. Lancet. 2012;379:1613–20. Ono R, Shimizu M, Yamamoto K, Umehara N, Manabe A. Kawasaki disease shock syndrome: case report and cytokine profiling. Pediatr Int. 2019;61:620–2. Dufort EM, Koumans EH, Chow EJ, Rosenthal EM, Muse A, Rowlands J, et al. Multisystem inflammatory syndrome in children in New York State. N Engl J Med. 2020;383:347–58. Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, et al. Multisystem inflammatory syndrome in U.S. children and adolescents. N Engl J Med. 2020;383:334–46. IDWR Surveillance Data Table 2020 week 34. https://www.niid.go.jp/niid/ja/data.html. Accessed 5 Sept 2020.